After Piper Sandler and Goldman Sachs gave Moderna (NASDAQ: MRNA) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr assigned a Buy rating to Moderna today and set a price target of $94.00. The company’s shares closed last Wednesday at $75.73.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.0% and a 41.7% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Moderna with a $92.29 average price target, representing a 19.1% upside. In a report issued on July 27, BMO Capital also maintained a Buy rating on the stock with a $94.00 price target.
The company has a one-year high of $95.21 and a one-year low of $11.54. Currently, Moderna has an average volume of 26.1M.
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.